Proteomic analysis of liver diseases: molecular mechanisms and biomarker discovery.
Liver diseases afflict more than 10% of the world population. Although the main risk factors are known and the population at risk is monitored, new biomarkers are urgently needed to allow early diagnosis and hence more effective therapeutic interventions. Here, we revise the contribution of proteomics to the study of liver diseases and its potential impact in the clinical practice is evaluated.
Santamaría
Enrique
E
Division of Hepatology and Gene Therapy, CIMA, University of Navarra, 31008 Pamplona, Spain.
Muñoz
Javier
J
Fernández-Irigoyen
Joaquín
J
Sesma
Laura
L
Odriozola
Leticia
L
Corrales
Fernando J
FJ
D015415:Biomarkers / Q000032:analysis*; D003300:Copper / Q000032:analysis; D006801:Humans; D007501:Iron / Q000032:analysis; D008107:Liver Diseases / Q000175:diagnosis* / Q000378:metabolism; D040901:Proteomics / Q000379:methods
D015415:Biomarkers; D003300:Copper; D007501:Iron